Dispersion in total cost of care for Medicare fee-for-service (FFS) patients with metastatic pancreatic cancer receiving FDA-approved/NCCN Category 1 regimens at 340B verus non-340B institutions. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results